DE2460042A1 - Pharmazeutisches mittel mit vasoregulatorischer wirkung auf die cerebrale blutzirkulation - Google Patents
Pharmazeutisches mittel mit vasoregulatorischer wirkung auf die cerebrale blutzirkulationInfo
- Publication number
- DE2460042A1 DE2460042A1 DE19742460042 DE2460042A DE2460042A1 DE 2460042 A1 DE2460042 A1 DE 2460042A1 DE 19742460042 DE19742460042 DE 19742460042 DE 2460042 A DE2460042 A DE 2460042A DE 2460042 A1 DE2460042 A1 DE 2460042A1
- Authority
- DE
- Germany
- Prior art keywords
- vincamine
- effect
- blood circulation
- cerebral blood
- pharmaceutical agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000002490 cerebral effect Effects 0.000 title claims description 16
- 230000017531 blood circulation Effects 0.000 title claims description 12
- 239000008177 pharmaceutical agent Substances 0.000 title claims description 8
- 230000003422 vasoregulatory effect Effects 0.000 title description 4
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 claims description 52
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 claims description 26
- 229960002726 vincamine Drugs 0.000 claims description 26
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 20
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 20
- 239000003826 tablet Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- RXPRRQLKFXBCSJ-LLQWEQGGSA-N ac1l3o7e Chemical compound C1=CC=C2C(CCN3CCC4)=C5C3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-LLQWEQGGSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000000304 vasodilatating effect Effects 0.000 description 4
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 210000002385 vertebral artery Anatomy 0.000 description 2
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 241000863486 Vinca minor Species 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000000001 effect on platelet aggregation Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 201000001948 hypertensive retinopathy Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 235000012751 sunset yellow FCF Nutrition 0.000 description 1
- 239000004173 sunset yellow FCF Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7346739A FR2255885B1 (cg-RX-API-DMAC7.html) | 1973-12-28 | 1973-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2460042A1 true DE2460042A1 (de) | 1975-07-10 |
Family
ID=9129848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19742460042 Withdrawn DE2460042A1 (de) | 1973-12-28 | 1974-12-19 | Pharmazeutisches mittel mit vasoregulatorischer wirkung auf die cerebrale blutzirkulation |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US3957981A (cg-RX-API-DMAC7.html) |
| BE (1) | BE823485A (cg-RX-API-DMAC7.html) |
| CA (1) | CA1027867A (cg-RX-API-DMAC7.html) |
| DE (1) | DE2460042A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2255885B1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB1440850A (cg-RX-API-DMAC7.html) |
| IL (1) | IL46315A (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2319359A1 (fr) * | 1975-07-31 | 1977-02-25 | Parcor | Medicament nouveau a base de vincanol et d'acide acetylsalicylique |
| US4122179A (en) * | 1976-06-03 | 1978-10-24 | Enrico Corvi Mora | Acid addition salts of vincamine and apovincamine |
| JPS5732281A (en) * | 1980-08-06 | 1982-02-20 | Sumitomo Chem Co Ltd | Nitrogen-containing polycyclic compound and its preparation |
| GB9010389D0 (en) * | 1990-05-09 | 1990-06-27 | Idb Holding Spa | Pharmaceutical formulations for the treatment of peripheral vascular diseases |
-
1973
- 1973-12-28 FR FR7346739A patent/FR2255885B1/fr not_active Expired
-
1974
- 1974-12-18 BE BE151613A patent/BE823485A/xx unknown
- 1974-12-19 DE DE19742460042 patent/DE2460042A1/de not_active Withdrawn
- 1974-12-23 IL IL46315A patent/IL46315A/xx unknown
- 1974-12-23 GB GB5560574A patent/GB1440850A/en not_active Expired
- 1974-12-23 US US05/536,941 patent/US3957981A/en not_active Expired - Lifetime
- 1974-12-27 CA CA216,978A patent/CA1027867A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IL46315A0 (en) | 1975-03-13 |
| IL46315A (en) | 1978-04-30 |
| CA1027867A (en) | 1978-03-14 |
| US3957981A (en) | 1976-05-18 |
| FR2255885B1 (cg-RX-API-DMAC7.html) | 1977-09-09 |
| GB1440850A (en) | 1976-06-30 |
| FR2255885A1 (cg-RX-API-DMAC7.html) | 1975-07-25 |
| BE823485A (fr) | 1975-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3688296T2 (de) | Arzneimittel zur behandlung von erbrechen. | |
| DE69432644T2 (de) | Kombination eines Angiotensin-II antagonistisch wirkendes Benzimidazols mit ein Diuretikum | |
| DE3534440A1 (de) | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes | |
| EP0351885A1 (de) | Verwendung von Pentoxifyllin zur Behandlung entzündlicher Erkrankungen | |
| DE3886075T2 (de) | Verwendung von Metformin zur Herstellung von Arzneimitteln. | |
| DE69326395T2 (de) | Spirooxathiolan-quinuclidin-Derivat zur Behandlung des Sjögren-Syndroms | |
| DE1802394C2 (de) | Arzneimittel mit antihypertensiver Wirkung, die [(2,6-Dichlorbenzyliden)-amino]-guanidin oder ein Säureadditionssalz davon enthalten | |
| CH668184A5 (de) | Verwendung von acyloxyalkanoylcholinsalzen fuer die herstellung eines mittels zur besserung und therapie von neuropsychiatrischen symptomen, die die demenz begleiten. | |
| DE68915269T2 (de) | Polyvalentes entzündungshemmendes mittel. | |
| DE2460042A1 (de) | Pharmazeutisches mittel mit vasoregulatorischer wirkung auf die cerebrale blutzirkulation | |
| EP0607777A2 (de) | Verwendung von Leflunomid zur Herstellung von Interleukin 8 | |
| DE2951671C2 (de) | Arzneimittelzubereitung mit Antithrombosewirkung und Hemmwirkung auf die Agglomeration der Blutplättchen | |
| DE68904475T2 (de) | Gewisse paf-antagonist/antihistamin-mischungen und verfahren. | |
| DE69003670T2 (de) | Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs. | |
| DE3739779A1 (de) | Pharmazeutische praeparate | |
| DE2708520C2 (cg-RX-API-DMAC7.html) | ||
| DE2212840A1 (de) | Mittel zur Behandlung kardiovaskulaerer Stoerungen und pharmazeutische Praeparate zu seiner Anwendung | |
| WO1998058639A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE60019591T2 (de) | Behandlung oder hemmung von koronarimplantat vasospasm | |
| DE2720194A1 (de) | Verwendung von trazodon und etoperidon zum behandeln des parkinson-tremors und anderer extra- pyramidaler syndrome | |
| DE3930282A1 (de) | Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit | |
| DE3406837C2 (cg-RX-API-DMAC7.html) | ||
| DE3439055A1 (de) | Substituierte 4h-3,1 benzoxazine und ein benzodiazepin-derivat enthaltendes arzneimittel | |
| DE2855306A1 (de) | Mittel zur senkung der herzfrequenz | |
| DE2951669C2 (de) | Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8141 | Disposal/no request for examination |